RA
RARE.US Ultragenyx
- Market cap
- USD 1.70B
- P/E
- -
- P/B
- 19.68x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RARE.US undervalued?
Graham numberThe Graham number of Ultragenyx cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ultragenyx fundamental analysis
No fundamental analysis for Ultragenyx yet.
Ultragenyx stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced …
Full company profileUltragenyx financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ultragenyx annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 133K | 2.61M | 51.5M | 104M | 271M | 351M | 363M | 434M | 560M | 673M | 697M |
| Gross Profit | 133K | 2.61M | 50.3M | 94.7M | 265M | 335M | 335M | 389M | 484M | 564M | 569M |
| Operating Income | -248M | -329M | -371M | -424M | -330M | -382M | -649M | -569M | -536M | -535M | -472M |
| EBITDA | -245M | -323M | -178M | -390M | -140M | -410M | -640M | -516M | -469M | -474M | -423M |
| Net Income | -246M | -302M | -198M | -403M | -187M | -454M | -707M | -607M | -569M | -575M | -527M |
| EPS | -6.21 | -7.12 | -3.97 | -7.12 | -3.07 | -6.70 | -10 | -8.25 | -6.29 | -5.83 | -5.16 |
| Balance Sheet | |||||||||||
| Total Assets | 541M | 491M | 720M | 1.14B | 1.76B | 1.52B | 1.55B | 1.49B | 1.50B | 1.53B | 1.19B |
| Total Liabilities | 66.7M | 107M | 111M | 482M | 605M | 600M | 1.19B | 1.22B | 1.24B | 1.61B | 1.56B |
| Shareholders' Equity | 474M | 383M | 609M | 654M | 1.15B | 923M | 352M | 275M | 255M | -80.0M | -376M |
| Cash & Short-term Investments | 498M | 244M | 460M | 755M | 1.20B | 740M | 748M | 577M | 610M | 693M | 266M |
| Total Debt | - | - | - | 37.0M | 48.2M | 42.0M | 31.6M | 43.2M | 40.3M | 1.28B | 1.19B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -161M | -254M | -291M | -345M | -132M | -339M | -380M | -475M | -414M | -466M | -449M |
| Capital Expenditure | 10.2M | 2.79M | 4.08M | 24.8M | 43.9M | 73.1M | 146M | 46.8M | 7.49M | 6.00M | 5.33M |
| Free Cash Flow | -171M | -257M | -295M | -370M | -176M | -412M | -527M | -522M | -422M | -472M | -455M |
| Ratios | |||||||||||
| ROE | -51.9% | -78.8% | -32.5% | -61.6% | -16.2% | -49.2% | -200.7% | -220.3% | -222.9% | - | - |
| ROA | -45.5% | -61.6% | -27.5% | -35.5% | -10.6% | -29.8% | -45.8% | -40.7% | -37.9% | -37.5% | -44.4% |
| Net Profit Margin | -184,867.7% | -11,567.3% | -383.7% | -388.3% | -68.8% | -129.2% | -194.7% | -139.7% | -101.6% | -85.4% | -75.5% |
| Debt to Equity | - | - | - | 0.06x | 0.04x | 0.05x | 0.09x | 0.16x | 0.16x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ultragenyx dividends
Ultragenyx has not paid dividends in the last 9 fiscal years.
Last stock split: 1:3 on Jan 17, 2014.
Who owns Ultragenyx
- Insiders 3.32%
- Institutions 96.68%
- Public & others 0.00%
- Shares outstanding 102M
- Free float 77.4M
Top funds holding RARE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 5.47M | 5.37% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.00M | 2.94% | +0.05% | Sep 2026 |
| iShares Russell 2000 ETF | 2.45M | 2.41% | 0.00% | Oct 2026 |
| Vanguard Strategic Equity Inv | 2.12M | 2.08% | +97.78% | Sep 2026 |
| Vanguard Small Cap Index | 2.11M | 2.07% | -1.96% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.17M | 1.15% | -4.74% | Sep 2026 |
| Fidelity Small Cap Index | 1.06M | 1.04% | +0.15% | Aug 2026 |
| AQR Long-Short Equity I | 915K | 0.90% | +12.73% | Jun 2026 |
| Strategic Advisers U.S. Total Stock | 859K | 0.84% | +68.09% | Sep 2026 |
| Vanguard Explorer Inv | 857K | 0.84% | +4.28% | Sep 2026 |
| Candriam Eqs L Biotech C USD Cap | 827K | 0.81% | 0.00% | Apr 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 760K | 0.75% | +58.54% | Sep 2026 |
| Carillon Scout Mid Cap I | 743K | 0.73% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 701K | 0.69% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 562K | 0.55% | +1.14% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 523K | 0.51% | +0.24% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 503K | 0.49% | +36.72% | Sep 2026 |
| iShares Russell 2000 Value ETF | 496K | 0.49% | 0.00% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 450K | 0.44% | +0.27% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 410K | 0.40% | -0.38% | Oct 2026 |
Top institutions holding RARE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 10.7M | 10.45% | +45.96% | Jun 2026 |
| RTW INVESTMENTS, LLC | 7.80M | 7.65% | +113.68% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.79M | 6.66% | +26.07% | Jun 2026 |
| AQR Capital Management LLC | 6.56M | 6.44% | +43.31% | Jun 2026 |
| State Street Corp | 6.16M | 6.04% | +22.65% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.30M | 4.22% | +2.55% | Jun 2026 |
| Two Sigma Investments LLC | 3.62M | 3.55% | +64.17% | Jun 2026 |
| Sands Capital Management, LLC | 3.16M | 3.10% | -1.75% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 2.94M | 2.88% | +105.42% | Jun 2026 |
| Frontier Capital Management CO Inc | 2.85M | 2.79% | +29.97% | Jun 2026 |
| Geode Capital Management, LLC | 2.58M | 2.53% | +39.44% | Jun 2026 |
| Bellevue Group AG | 1.98M | 1.95% | -16.69% | Jun 2026 |
| D. E. Shaw & Co LP | 1.73M | 1.70% | +37.21% | Jun 2026 |
| Sofinnova Ventures | 1.72M | 1.69% | -45.40% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.58M | 1.55% | +229.17% | Jun 2026 |
| GW&K Investment Management, LLC | 1.48M | 1.45% | -8.31% | Jun 2026 |
| MPM Oncology Impact Management LP | 1.42M | 1.39% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.36M | 1.33% | +68.70% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.32M | 1.30% | -11.71% | Jun 2026 |
| Wellington Management Company LLP | 1.25M | 1.23% | -52.65% | Jun 2026 |
Ultragenyx company profile
- Company name
- Ultragenyx
- Ticker
- RARE.US
- Exchange
- USA Stocks
- Listed since
- Jan 31, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,371
- Fiscal year end
- December
- Address
- 60 Leveroni Court, Novato, CA, United States, 94949
- Phone
- 415 483 8800
- Website
- ultragenyx.com
About Ultragenyx
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx management
10- Dr. Emil D. Kakkis M.D., Ph.D.Founder, President, CEO & Director · born 1960
- Mr. Howard HornExecutive VP of Corporate Strategy & CFO · born 1979
- Ms. Karah Herdman Parschauer J.D.Chief Legal Officer & Executive VP of Corporate Affairs · born 1978
- Mr. Erik Harris M.B.A.Executive VP & Chief Commercial Officer · born 1970
- Dr. Eric Crombez M.D.Chief Medical Officer & Executive VP · born 1973
- Mr. Theodore A. HuizengaSenior VP, Corporate Controller & Principal Accounting Officer · born 1971
- Mr. Ernie W. MeyerChief Human Resources Officer & Executive VP · born 1965
- Mr. Vimal SrivastavaSenior Vice President of Business Development & Alliance Management · born 1965
- Mr. Dennis Karl HuangChief Technical Operations Officer and Executive VP of Gene Therapy Operations
- Mr. John Richard Pinion IIChief Quality Operations Officer & Executive VP of Translational Sciences · born 1966